Iranian
Biomedical Journal
Volume 26, Issue 3 (5-2022)
IBJ 2022, 26(3): 175-182 |
Back to browse issues page
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Niknam K, Safaei A, Ghaderi A. Evaluation of the Prognostic Value of CD56 (140 kDa Isoform) Expression in Breast Cancer Tissues: an Eight-Year Retrospective Study. IBJ 2022; 26 (3) :175-182
URL: http://ibj.pasteur.ac.ir/article-1-3596-en.html
URL: http://ibj.pasteur.ac.ir/article-1-3596-en.html
Abstract:
Background: Identification of specific antigens is highly beneficial for early detection, diagnosis, staging, and outcome prediction of cancer. This study aimed to evaluate the expression and prognostic value of CD56 (140 kDa isoform) in invasive ductal carcinoma (IDC).
Methods: Sixty-five patients with IDC who underwent radical surgery or mastectomy as the primary treatment were included. Proper formalin-fixed and paraffin embedded tissue blocks of the patients were prepared and stained by IHC for CD56 (140 kDa isoform) molecule. Chi-square and fisher exact tests were used to compare the results against the clinicopathologic data of patients. Kaplan-Meier and log-rank test were employed to study the prognostic value of the target antigen.
Results: The expression pattern of CD56 was granular and cytoplasmic. There were significant associations between the intensity of CD56 expression in invasive cells and carcinoma in situ (p = 0.005) and normal ducts (p = 0.010). Among all clinicipathologic parameters, there was only a significant association between the expression of estrogen receptor (ER) and CD56 (p = 0.023). Neither OS (overall survival; p = 0.356) nor DFS (disease-free survival; p = 0.976) had significant correlation with CD56 expression.
Conclusion: Our data indicated that the CD56 marker offers no prognostic value in terms of predicting the OS or DFS for up to eight years after primary surgery. Furthermore, the intensity of its expression is similar between normal, non-invasive, and invasive cells. Considering the generally better outcome of ER+ BC patients than their ER-counterparts, the CD56 marker may be indirectly associated with a more favorable prognosis among IDC patients.
Methods: Sixty-five patients with IDC who underwent radical surgery or mastectomy as the primary treatment were included. Proper formalin-fixed and paraffin embedded tissue blocks of the patients were prepared and stained by IHC for CD56 (140 kDa isoform) molecule. Chi-square and fisher exact tests were used to compare the results against the clinicopathologic data of patients. Kaplan-Meier and log-rank test were employed to study the prognostic value of the target antigen.
Results: The expression pattern of CD56 was granular and cytoplasmic. There were significant associations between the intensity of CD56 expression in invasive cells and carcinoma in situ (p = 0.005) and normal ducts (p = 0.010). Among all clinicipathologic parameters, there was only a significant association between the expression of estrogen receptor (ER) and CD56 (p = 0.023). Neither OS (overall survival; p = 0.356) nor DFS (disease-free survival; p = 0.976) had significant correlation with CD56 expression.
Conclusion: Our data indicated that the CD56 marker offers no prognostic value in terms of predicting the OS or DFS for up to eight years after primary surgery. Furthermore, the intensity of its expression is similar between normal, non-invasive, and invasive cells. Considering the generally better outcome of ER+ BC patients than their ER-counterparts, the CD56 marker may be indirectly associated with a more favorable prognosis among IDC patients.
Type of Study: Full Length/Original Article |
Subject:
Molecular Immunology & Vaccines
References
1. DeSantis CE, Fedewa SA, Goding Sauer A, Kramer JL, Smith RA, Jemal A. Breast cancer statistics, 2015: Convergence of incidence rates between black and white women. Cancer journal for clinicians 2016; 66(1): 31-42. [DOI:10.3322/caac.21320]
2. Tao Z, Shi A, Lu C, Song T, Zhang Z, Zhao J. Breast cancer: epidemiology and etiology. Cell biochemistry and biophysics 2015; 72(2): 333-338. [DOI:10.1007/s12013-014-0459-6]
3. Rezaianzadeh A, Jalali M, Maghsoudi A, Mokhtari AM, Azgomi SH, Dehghani SL. The overall 5-year survival rate of breast cancer among Iranian women: a systematic review and meta-analysis of published studies. Breast disease 2017; 37(2): 63-68. [DOI:10.3233/BD-160244]
4. Kristiansen G, Winzer K-J, Mayordomo E, Bellach J, Schlüns K, Denkert C, Dahl E, Pilarsky C, Altevogt P, Guski H, Dietel M. CD24 expression is a new prognostic marker in breast cancer. Clinical cancer research 2003; 9(13): 4906-4913.
5. Anderson WF, Chatterjee N, Ershler WB, Brawley OW. Estrogen receptor breast cancer phenotypes in the Surveillance, Epidemiology, and End Results database. Breast cancer research and treatment 2002; 76(1): 27-36. [DOI:10.1023/A:1020299707510]
6. Perou CM, Sørlie T, Eisen MB, Van De Rijn M, Jeffrey SS, Rees CA, Akslen LA, Fluge O, Pergamenschikov A, Williams C, Zhu SX, Lønning PE, Børresen-Dale AL, Brown PO, Botstein D. Molecular portraits of human breast tumours. Nature 2000; 406(6797): 747-752. [DOI:10.1038/35021093]
7. Gattenlöhner S, Stühmer T, Leich E, Reinhard M, Etschmann B, Völker H-U, Rosenwald A, Serfling E, Christian Bargou R, Ertl G, Einsele H, Müller-Hermelink H-K. Specific detection of CD56 (NCAM) isoforms for the identification of aggressive malignant neoplasms with progressive development. The American journal of pathology 2009; 174(4): 1160-1171. [DOI:10.2353/ajpath.2009.080647]
8. Van Acker HH, Capsomidis A, Smits EL, Van Tendeloo VF. CD56 in the immune system: more than a marker for cytotoxicity? Frontiers in immunology 2017; 8: 892. [DOI:10.3389/fimmu.2017.00892]
9. Tur MK, Etschmann B, Benz A, Leich E, Waller C, Schuh K, Rosenwald A, Ertl G, Kienitz A, Haaf AT, Bräuninger A, Gattenlöhner S. The 140-kD isoform of CD56 (NCAM1) directs the molecular pathogenesis of ischemic cardiomyopathy. The American journal of pathology 2013; 182(4): 1205-1218. [DOI:10.1016/j.ajpath.2012.12.027]
10. Völker HU, Engert S, Cramer A, Schmidt M, Kämmerer U, Müller-Hermelink HK, Gattenlöhner S. Expression of CD56 isoforms in primary and relapsed adult granulosa cell tumors of the ovary. Diagnostic pathology 2008; 3(1): 1-7. [DOI:10.1186/1746-1596-3-29]
11. Ghaderi F, Ahmadvand S, Ramezani A, Montazer M, Ghaderi A. Production and characterization of monoclonal antibody against a triple negative breast cancer cell line. Biochemical and biophysical research communications 2018; 505(1): 181-186. [DOI:10.1016/j.bbrc.2018.09.087]
12. Hortobagyi GN, Edge SB, Giuliano A. New and important changes in the TNM staging system for breast cancer. American society of clinical oncology educational book 2018; 38: 457-467. [DOI:10.1200/EDBK_201313]
13. Zhang J, Zhao B, Jin F. The assessment of 8th edition AJCC prognostic staging system and a simplified staging system for breast cancer: The analytic results from the SEER database. The breast journal 2019; 25(5): 838-847. [DOI:10.1111/tbj.13347]
14. Aref S, Azmy E, El-Bakry K, Ibrahim L, Mabed M. Prognostic impact of CD200 and CD56 expression in adult acute lymphoblastic leukemia patients. Hematology 2018; 23(5): 263-2670. [DOI:10.1080/10245332.2017.1404276]
15. Aloysius M, Zaitoun A, Awad S, Ilyas M, Rowlands B, Lobo D. Mucins and CD56 as markers of tumour invasion and prognosis in periampullary cancer. British journal of surgery 2010; 97(8): 1269-1278. [DOI:10.1002/bjs.7107]
16. Mechtersheimer G, Staudter M, Möller P. Expression of the natural killer (NK) cell-associated antigen CD56 (Leu-19), which is identical to the 140-kDa isoform of N-CAM, in neural and skeletal muscle cells and tumors derived therefrom. Annals of the New York Academy of Sciences 1992; 650: 311-316. [DOI:10.1111/j.1749-6632.1992.tb49143.x]
17. Zeromski J, Nyczak E, Dyszkiewicz W. Significance of cell adhesion molecules, CD56/NCAM in particular, in human tumor growth and spreading. Folia histochemica et cytobiologica 2001; 39: 36-37.
18. Muthusamy S, Shah SA, Suhaimi SNA, Kassim N, Mahasin M, Saleh MFM, Md Isa N. CD56 expression in benign and malignant thyroid lesions. The Malaysian journal of pathology 2018; 40(2): 111-119.
19. Abouhashem NS, Talaat SM. Diagnostic utility of CK19 and CD56 in the differentiation of thyroid papillary carcinoma from its mimics. Pathology research and practice 2017; 213(5): 509-517. [DOI:10.1016/j.prp.2017.01.017]
20. Socinski MA, Kaye FJ, Spigel DR, Kudrik FJ, Ponce S, Ellis PM, Majem M, Lorigan P, Gandhi L, Gutierrez ME, Nepert D, Corral J, Paz Ares L. Phase 1/2 study of the CD56-targeting antibody-drug conjugate lorvotuzumab mertansine (IMGN901) in combination with carboplatin/etoposide in small-cell lung cancer patients with extensive-stage disease. Clinical lung cancer 2017; 18(1): 68-76. [DOI:10.1016/j.cllc.2016.09.002]
21. Arciero CA, Guo Y, Jiang R, Behera M, O'Regan R, Peng L, Li X. ER+/HER2+ Breast Cancer Has Different Metastatic Patterns and Better Survival Than ER-/HER2+ Breast Cancer. Clinical breast cancer 2019; 19(4): 236-245. [DOI:10.1016/j.clbc.2019.02.001]
22. Sugiura H, Toyama T, Hara Y, Zhang Z, Kobayashi S, Fujii Y, Iwase H, Yamashita H. Expression of Estrogen Receptor β Wild-type and its Variant ERβcx/β2 is Correlated with Better Prognosis in Breast Cancer. Japanese journal of clinical oncology 2007; 37(11): 820-828. [DOI:10.1093/jjco/hym114]
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
IBJ is a member of Committee on Publication Ethics (COPE)
and follows its guidelines |
The articles of this journal are licensed under
a Creative Commons Attribution-NonDerivatives 4.0 International License. .png) |
 IBJ is owned and published by Pasteur Institute of Iran |